<DOC>
	<DOCNO>NCT01424566</DOCNO>
	<brief_summary>The primary objective study determine efficacy Sativex , compare placebo , adjunctive medication relieve persistent chronic pain ( breakthrough pain ) patient advanced cancer , pain even optimized/maximized chronic opioid therapy . This multi-center study conduct two part . All participant enrol trial receive Sativex one two part study , know part . Eligible patient require stop current treatment medication .</brief_summary>
	<brief_title>A Two-Part Study SativexÂ® Oromucosal Spray Relieving Uncontrolled Persistent Pain Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<criteria>Inclusion Criteria ( abbreviate ) : The patient advance cancer know curative therapy The patient clinical diagnosis cancer relate pain , alleviate current optimized opioid treatment The patient receive optimized maintenance dose Step III opioid therapy , preferably sustain release preparation , also allow regular maintenance dose around clock use immediate release preparation The patient receive daily maintenance dose Step III opioid therapy less equal total daily opioid dose 500 mg/day morphine equivalence ( include maintenance breakthrough opioids ) The patient use one type breakthrough opioid analgesia Exclusion Criteria ( abbreviate ) : Have plan clinical intervention would affect pain ( e.g. , chemotherapy radiation therapy , clinical judgment investigator , would expect affect pain ) The patient currently use use cannabis cannabinoid base medication within 30 day study entry unwilling abstain duration study Has experience myocardial infarction clinically significant cardiac dysfunction within last 12 month cardiac disorder , opinion investigator would put patient risk clinically significant arrhythmia myocardial infarction Has significantly impair renal function Has significantly impair hepatic function Female patient childbearing potential male patient whose partner childbearing potential , unless willing ensure partner use effective contraception , example , oral contraception , double barrier , intrauterine device , study three month thereafter ( however , male condom use conjunction female condom may prove effective )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cancer pain</keyword>
	<keyword>opioid therapy</keyword>
	<keyword>inadequate analgesia</keyword>
	<keyword>optimize chronic opioid therapy</keyword>
</DOC>